Rhéaume Marc-André, Vavvas Demetrios
Retina Service, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
Semin Ophthalmol. 2010 Sep-Nov;25(5-6):295-302. doi: 10.3109/08820538.2010.518865.
It is now well recognized that vitreous plays an important role in the pathogenesis of various retinal disorders. In many instances it can be addressed with pars plana vitrectomy, although this approach, like any surgery, has its limitations. The search for alternatives or adjunct to surgery has led to the development of pharmacologic vitreolysis. The use of intravitreal agents to alter the vitreous in order to reduce or eliminate its role in disease seems promising. The purpose of this article is to summarize the present knowledge on pharmacologic vitreolysis. A review of the different agents used and of ongoing trials will be presented. Also, current understanding of vitreous structure and its interaction with the retina will be discussed.
现在人们已经充分认识到，玻璃体在各种视网膜疾病的发病机制中起着重要作用。在许多情况下，可以通过玻璃体切除术来解决，尽管这种方法与任何手术一样都有其局限性。对手术替代方法或辅助方法的探索导致了药物性玻璃体溶解术的发展。使用玻璃体内药物来改变玻璃体，以减少或消除其在疾病中的作用似乎很有前景。本文的目的是总结目前关于药物性玻璃体溶解术的知识。将介绍对所使用的不同药物和正在进行的试验的综述。此外，还将讨论目前对玻璃体结构及其与视网膜相互作用的理解。
